Zai Lab Limited (ZLAB) News
Follow Zai Lab Limited (ZLAB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Zai Lab Q3 Loss Widens as Revenue Declines
Zai Lab reported a wider Q3 loss and declining revenue.
EQUITY | Nov 05, 2026, 02:29 PM UTC
M
Zai Lab Reports Q3 Revenue of $108.2 Million
Zai Lab reported Q3 revenue of $108.2 million, versus a FactSet estimate of $107.9 million.
EQUITY | Nov 05, 2026, 11:35 AM UTC
M
Zai Lab Announces $250 Million Private Placement
Zai Lab entered into a securities purchase agreement to sell 11,340,000 ADSs, each representing ten ordinary shares, to investors.
EQUITY | Oct 23, 2026, 12:59 AM UTC
L
Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Zai Lab Limited (NASDAQ:ZLAB; HKEX:9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for the first-line treatment of extensive-stage small cell lung c
NEWS | Sep 29, 2026, 11:01 AM UTC
H
The Insider Report: The Leaders Have Taken Off
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the fou
LIVE | Sep 28, 2026, 12:46 PM UTC
L
ZLAB - U.S. FDA grants orphan drug designation to Zai lab’s dll3-targeting Adc zocilurtatug pelitecan (zoci) for the treatment of neuroendoc
ZLAB - U.S. FDA grants orphan drug designation to Zai lab’s dll3-targeting Adc zocilurtatug pelitecan (zoci) for the treatment of neuroendocrine carcinomas (necs)
REGULATION | Aug 03, 2026, 11:06 AM UTC